|
Joachim Yahalom,MD1,Tim Illidge,MD,PhD2,Lena Specht,MD,PhD3,Richard T.Hoppe,MD4,Ye-Xiong Li,MD5,Richard Tsang,MD6,and Andrew Wirth,MD7,on behalf of International Lymphoma Radiation Oncology Group |
|
|
1Department of Radiation Oncology,Memorial Sloan-Kettering Cancer Center,New York,New York;2Institute of Cancer Sciences,University of Manchester,Manchester Academic Health Sciences Centre,The Christie National Health Service Foundation Trust,Manchester,United Kingdom;3Department of Oncology and Hematology,Rigshospitalet,University of Copenhagen,Copenhagen,Denmark;4Department of Radiation Oncology,Stanford University,Palo Alto,California;5Department of Radiation Oncology,Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,People’s Republic of China;6Department of Radiation Oncology,Princess Margaret Hospital,University of Toronto,Toronto,Ontario,Canada;and 7Division of Radiation Oncology,Peter MacCallum Cancer Institute,St. Andrews Place,East Melbourne,Australia Yang Zhuanbo,Liu Xin,Qi Shunan,Li Yexiong,Translation Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100005,China (Yang ZB);Department of Radiation Oncology,National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China (Liu X,Qi SN,Li YX) |
|
